{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:41:16Z","timestamp":1769942476457,"version":"3.49.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.drudis.2012.07.011","type":"journal-article","created":{"date-parts":[[2012,8,4]],"date-time":"2012-08-04T02:03:21Z","timestamp":1344045801000},"page":"11-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout"],"prefix":"10.1016","volume":"18","author":[{"given":"Roberto E.","family":"Favoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Alama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2012.07.011_bib0005","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/91.8.675","article-title":"Annual report to the nation on the status of cancer, 1973\u20131996, with a special section on lung cancer and tobacco smoking","volume":"91","author":"Wingo","year":"1999","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.drudis.2012.07.011_bib0010","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA: Cancer J. Clin."},{"key":"10.1016\/j.drudis.2012.07.011_bib0015","unstructured":"Commonly diagnosed cancers worldwide. Cancer Research UK, April 2005. Retrieved 2008, http:\/\/info.cancerresearchhuk.org\/cancerstats\/geographic\/world\/commoncancers\/"},{"key":"10.1016\/j.drudis.2012.07.011_bib0020","unstructured":"American Cancer Society: Cancer Facts and Figures 2012. Atlanta, GA, http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-031941.pdf"},{"key":"10.1016\/j.drudis.2012.07.011_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.20851","article-title":"Gene therapy for lung cancer","volume":"99","author":"Toloza","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.drudis.2012.07.011_bib0030","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer","volume":"350","author":"Arrigada","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0040","volume":"Vol. 1","author":"De Vita","year":"2005"},{"key":"10.1016\/j.drudis.2012.07.011_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/thorax.57.1.20","article-title":"Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer: a systematic review","volume":"57","author":"Clegg","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2012.07.011_bib0050","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","article-title":"Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma","volume":"166","author":"Favoni","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0055","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"Erb-B receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2012.07.011_bib0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/156800910791054130","article-title":"Gefitinib targets EGFR dimerization and ERK1\/2 phosphorylation to inhibit pleural mesothelioma cell proliferation","volume":"2","author":"Favoni","year":"2010","journal-title":"Curr. Cancer Drug Target"},{"key":"10.1016\/j.drudis.2012.07.011_bib0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.lungcan.2008.06.021","article-title":"Impact of EGFR mutation analysis in non-small cell lung cancer","volume":"63","author":"Yamamoto","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00000441-200603000-00006","article-title":"Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact","volume":"331","author":"Dowell","year":"2006","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.drudis.2012.07.011_bib0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/modpathol.2011.215","article-title":"Molecular pathology of lung cancer: key to personalized medicine","volume":"25","author":"Cheng","year":"2012","journal-title":"Modern Pathol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0080","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2006.12.008","article-title":"EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences","volume":"62","author":"Dassonville","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0095","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinoma","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0100","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4\u2013ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Jussi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B\u2013RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0110","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0115","first-page":"1997","article-title":"Expression of the Met\/HGF receptor in normal and neoplastic tissues","volume":"6","author":"Di Renzo","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2012.07.011_bib0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1023768811842","article-title":"c-Met: structure, functions and potential for therapeutic inhibition","volume":"22","author":"Ma","year":"2003","journal-title":"Cancer Met. Rev"},{"key":"10.1016\/j.drudis.2012.07.011_bib0125","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1038\/bjc.1998.361","article-title":"Paracrine effects on hepatocyte growth factors\/scatter factor on non-small cell lung carcinoma cell lines","volume":"77","author":"Yi","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0130","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","article-title":"Targeting the cMet signaling pathway in cancer","volume":"12","author":"Peruzzi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.lungcan.2008.06.011","article-title":"MET as a target for treatment of chest tumours","volume":"63","author":"Cipriani","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9107-6","article-title":"The Met tyrosine kinase receptor in development and cancer","volume":"27","author":"Gentile","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.drudis.2012.07.011_bib0145","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Invasive growth: a Met driven genetic programme for cancer and stem cells","volume":"6","author":"Boccaccio","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0150","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0155","article-title":"c-Met expression\/activation, functions and mutation in non-small cell lung cancer","volume":"45","author":"Ma","year":"2004","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1349-7006.2003.tb01440.x","article-title":"NK4 (HGF-antagonist\/angiogenesis inhibitor) in cancer biology and therapeutics","volume":"94","author":"Matsumoto","year":"2003","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drudis.2012.07.011_bib0165","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/0008-5472.CAN-05-3329","article-title":"Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor\/c-Met-dependent human tumors","volume":"66","author":"Burgess","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0485","doi-asserted-by":"crossref","unstructured":"Gordon, M.S. et al. (2007) Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumours. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25 [18S (20 Suppl.)], 3551","DOI":"10.1200\/jco.2007.25.18_suppl.3551"},{"key":"10.1016\/j.drudis.2012.07.011_bib0175","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1158\/1078-0432.CCR-08-0108","article-title":"A novel recombinant soluble splice variant of Met is a potent antagonist of the Hepatocyte Growth Factor\/Scatter Factor-Met pathway","volume":"14","author":"Zohar","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0180","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1172\/JCI22235","article-title":"An uncleavable form of pro-scatted factor suppresses the tumor growth and dissemination in mice","volume":"114","author":"Mazzone","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2012.07.011_bib0185","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1038\/sj.onc.1207691","article-title":"The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants","volume":"23","author":"Berthou","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2012.07.011_bib0190","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1073\/pnas.0508776103","article-title":"Amplification of Met may identity a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA665752","volume":"103","author":"Smolen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drudis.2012.07.011_bib0195","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/0008-5472.CAN-06-4416","article-title":"A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts","volume":"67","author":"Puri","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0200","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, exibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0205","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","article-title":"ARQ197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity","volume":"9","author":"Munshi","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2012.07.011_bib0210","doi-asserted-by":"crossref","first-page":"20666","DOI":"10.1074\/jbc.M110.213801","article-title":"Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal\u2013epithelial transition factor (c-Met) protein autophosphorylation by ARQ197","volume":"286","author":"Eathiraj","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.07.011_bib0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molmed.2009.11.005","article-title":"Developing c-Met pathway inhibitors for cancer therapy: progress and challenges","volume":"16","author":"Liu","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0225","series-title":"EORTC-NCI-AACR Int Congress","article-title":"Targeting Met with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design","author":"Janne","year":"2008"},{"key":"10.1016\/j.drudis.2012.07.011_bib0230","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion and metastasis by Exel-2880 (XL-880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Quian","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0235","doi-asserted-by":"crossref","first-page":"Abs3526","DOI":"10.1200\/jco.2007.25.18_suppl.3526","article-title":"Phase I experience with c-Met inhibitor XL880 administered orally to patients (pts) with solid tumors","volume":"2518S","author":"Eder","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0240","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1349-7006.2009.01343.x","article-title":"E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models","volume":"101","author":"Nakagawa","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drudis.2012.07.011_bib0245","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-11-1171","article-title":"Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth-factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer","volume":"18","author":"Wang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0250","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1158\/1535-7163.MCT-09-0477","article-title":"SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo","volume":"8","author":"Buchanan","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2012.07.011_bib0255","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijrobp.2006.07.1040","article-title":"c-Met inhibition radiosensitizes melanoma by inhibiting double strand DNA repair","volume":"66","author":"Welsh","year":"2006","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"10.1016\/j.drudis.2012.07.011_bib0260","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1038\/sj.onc.1205622","article-title":"K252a inhibits the oncogenic properties of Met, the HGF receptor","volume":"21","author":"Morotti","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2012.07.011_bib0265","doi-asserted-by":"crossref","first-page":"29274","DOI":"10.1074\/jbc.274.41.29274","article-title":"A peptide representing the carboxy-terminal tail of the Met receptor inhibits kinase activity and invasive growth","volume":"274","author":"Bardelli","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.07.011_bib0270","first-page":"5604","article-title":"In vitro and in vivo activity of fully-human monoclonal antibody antagonists to c-Met protein tyrosine kinase","volume":"43","author":"Morton","year":"2003","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0275","first-page":"1424","article-title":"Inhibition of c-Met activation by a one-armed antibody","volume":"44","author":"Schwall","year":"2004","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0280","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2012.07.011_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.JTO.0000283232.53465.68","article-title":"Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model","volume":"2","author":"Shimamura","year":"2007","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0290","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2008.18.6015","article-title":"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study","volume":"27","author":"Wang","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0295","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0300","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.drudis.2011.02.005","article-title":"Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?","volume":"17","author":"Alama","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2012.07.011_bib0305","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/cncr.21227","article-title":"Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma","volume":"104","author":"Pusztai","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0310","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1158\/0008-5472.CAN-11-1780","article-title":"Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)","volume":"72","author":"Holt","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0315","doi-asserted-by":"crossref","first-page":"e14124","DOI":"10.1371\/journal.pone.0014124","article-title":"Combination treatment with MEK and Akt inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo","volume":"5","author":"Meng","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.07.011_bib0320","doi-asserted-by":"crossref","first-page":"e20899","DOI":"10.1371\/journal.pone.0020899","article-title":"The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo","volume":"6","author":"Xu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.07.011_bib0325","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinase involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0330","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2012.07.011_bib0335","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1535-7163.MCT-11-0185","article-title":"PF-04691502, a potent and selective oral inhibitor of PI3K kinases with antitumor activity","volume":"10","author":"Yuan","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2012.07.011_bib0340","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-10-2668","article-title":"MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents","volume":"71","author":"Fan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0345","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer nature medicine","volume":"18","author":"King","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0350","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2012.07.011_bib0355","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2012.07.011_bib0360","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0365","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","article-title":"Non-small-cell lung cancer","volume":"378","author":"Goldstraw","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2012.07.011_bib0370","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American Society for Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR). Mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"Keedy","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0375","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multi-centre, open-label, randomized, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0380","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0385","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2012.07.011_bib0390","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2010.11.007","article-title":"Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors","volume":"73","author":"Zhao","year":"2011","journal-title":"Lung Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.drudis.2012.07.011_bib0395","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1359-6349(07)70502-5","article-title":"A Phase I and pharmacokinetic (PK) study of BIBW2992, an oral irreversible dual EGFR\/HER2 inhibitor","author":"Plummer","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","author":"Miller","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0405","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","author":"Yang","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0410","unstructured":"Study to evaluate erlotinib with or without SNDX-275 in the treatment of patients with advanced NSCLC. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00602030 (accessed July 2012)"},{"key":"10.1016\/j.drudis.2012.07.011_bib0415","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","article-title":"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0420","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ejca.2012.02.001","article-title":"ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development","volume":"48","author":"Scagliotti","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0425","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0430","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2008.17.3138","article-title":"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer","volume":"26","author":"Heymach","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0435","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2008.18.6015","article-title":"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study","volume":"27","author":"Natale","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0440","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind Phase III trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0445","first-page":"396s","article-title":"Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, non-small cell lung cancer: a North Central Cancer Treatment Group Study","volume":"25","author":"Blumenschein","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0450","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1758834011408636","article-title":"The role of the c-Met pathway in lung cancer and the potential for targeted therapy","volume":"3","author":"Sattler","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0455","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-10-1371","article-title":"Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer","volume":"16","author":"Suda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2012.07.011_bib0460","first-page":"112","article-title":"XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC","volume":"13","author":"Zhang","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2012.07.011_bib0465","article-title":"Phase I study of ARQ197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase II dose","volume":"2518S","author":"Garcia","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0470","article-title":"Rationale and design of MARQUEE: a Phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer","author":"von Pawel","year":"2012","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.drudis.2012.07.011_bib0475","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","article-title":"Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer","volume":"29","author":"Sequist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2012.07.011_bib0480","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-11-1171","article-title":"Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer","volume":"18","author":"Scagliotti","year":"2012","journal-title":"Clin. Cancer Res."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644612002656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644612002656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:13:09Z","timestamp":1761221589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644612002656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":96,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1359644612002656"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2012.07.011","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2012.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}